Literature DB >> 31369187

Biphasic squamoid alveolar renal carcinoma with positive CD57 expression: A clinicopathologic study of three cases.

Luting Zhou1, Haimin Xu1, Yangfan Zhou2, Jun Zhou1, Peipei Zhang1, Xiaoqun Yang1, Chaofu Wang1.   

Abstract

Biphasic squamoid alveolar renal cell carcinoma (BSARCC) is a rare and recently characterized form of papillary renal cell carcinoma (PRCC). Herein, we describe three cases of BSARCC that were CD57+. Among a total of 90 cases of PRCC, three cases were found to be consistent with a diagnosis of BSARCC. In addition to reviewing these cases, we reviewed the relevant literature pertaining to this form of cancer and assessed the immunohistochemical staining for CD57 on the available tumor samples. The three BSARCC cases in the present study were composed of two primary populations of cells. Tumors stained positive for CK, PAX8, CK7, CK19, AMACR, EMA, and vimentin. Larger cells expressed detectable levels of cyclin D1, and expression of CD57 was limited to the larger cells. All three patients were alive and free of disease during the most recent follow-up. Our results suggest that the CD57 positivity of at least a subset of cases should necessitate their differentiation from cases of metanephric adenoma.
© 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  BSARCC; CD57; cyclin D1; metanephric adenoma; papillary RCC

Mesh:

Substances:

Year:  2019        PMID: 31369187     DOI: 10.1111/pin.12844

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Biphasic squamoid alveolar renal cell carcinoma: description of a rare case and a literature analysis.

Authors:  Yang Zhang; Yuyun Xu; Taihen Yu; Junfa Chen; Ming Zhao; Chunmiao Lin
Journal:  Quant Imaging Med Surg       Date:  2022-07

Review 2.  Papillary renal cell carcinoma: current and controversial issues.

Authors:  Silvia Angori; João Lobo; Holger Moch
Journal:  Curr Opin Urol       Date:  2022-06-09       Impact factor: 2.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.